NCT01798979 - A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Healthy

Interventions

DRUG

GLPG0634

Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.

DRUG

Midazolam

Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)

Trial Locations (1)

Covance Clinical Research Unit, Madison